Current State of Immunotherapy for Treatment of Glioblastoma

At this time, there are no FDA-approved immune therapies for glioblastoma (GBM) despite many unique therapies currently in clinical trials. GBM is a highly immunosuppressive tumor and there are limitations to a safe immune response in the central nervous system. To date, there have been several fail...

Descripción completa

Detalles Bibliográficos
Autores principales: McGranahan, Tresa, Therkelsen, Kate Elizabeth, Ahmad, Sarah, Nagpal, Seema
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2019
Materias:
Neuro-oncology (GJ Lesser, Section Editor)
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6394457/
https://www.ncbi.nlm.nih.gov/pubmed/30790064
http://dx.doi.org/10.1007/s11864-019-0619-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6394457/
https://www.ncbi.nlm.nih.gov/pubmed/30790064
http://dx.doi.org/10.1007/s11864-019-0619-4

Ejemplares similares